Virupaksha Organics Ltd. has emerged as a leader in the pharmaceutical industry, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs). Founded in 2003, the company has built a reputation for innovation, quality, and sustainability. Under the dynamic leadership of Mr. Chandra Mouliswar Reddy Gangavaram, Virupaksha has grown its operations significantly, with state-of-the-art manufacturing facilities in Telangana, India.
The company’s facilities in Kazipally and Pashamylaram are certified by international and national regulatory bodies, including ISO 9001, ISO 14001, ISO 45001, ISO 50001, and GMP standards, ensuring that Virupaksha meets the highest levels of quality and safety in its production processes. These certifications highlight the company’s commitment to environmental sustainability, occupational safety, and best industry practices.
Virupaksha Organics is committed to excellence, innovation, and customer satisfaction, with a focus on developing sustainable solutions for the pharmaceutical industry. The company’s products are trusted by major pharmaceutical firms globally, as it continues to make strides towards becoming a research-driven organization. With a forward-thinking management team and a clear vision for the future, Virupaksha Organics is poised for rapid growth and continues to play a key role in advancing global healthcare.
As part of its corporate social responsibility (CSR), Virupaksha has initiated numerous welfare programs aimed at uplifting local communities and supporting environmental conservation, reinforcing its reputation as a responsible corporate citizen. With continuous advancements and strategic partnerships, Virupaksha Organics Ltd. is well-positioned to expand its global footprint and contribute to the evolving pharmaceutical landscape.
Other News
- Lilly and EVA Pharma’s Locally Manufactured Insulin Approved in Egypt December 18, 2024 9:11 pm The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company. Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human …
- Stocks in news: Mobikwik, Vishal Mega Mart, Ambuja Cements, Adani Energy, Auro Pharma & Sai Life December 18, 2024 2:44 am Indian benchmark indices settled with big cuts on Tuesday amid the pessimism of hawkish signals from the US Federal Reserve. BSE Sensex tanked 1,064.12 points, or 1.30 per cent, to end at 80,684.45. NSE's Nifty50 crashed 332.25 points or 1.35 per cent, …
- Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt December 17, 2024 11:18 am This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income countries annually by 2030 INDIANAPOLIS and CAIRO, Dec. 17, 2024 /PRNewswire/ -- …
- New HSR Rules: Impacts to the Pharma Industry December 16, 2024 11:21 pm Click here to listen to the audio On this Ropes & Gray podcast, strategic transactions partner Hannah England is joined by antitrust partners Jackie Grise and Zak Goodwin to discuss the practical implications of the new Hart–Scott–Rodino (“HSR”) Act …
- Stocks in news: Wipro, Paytm, RITES, Welspun Corp, CEAT, Biocon, JSW Energy & Suven Pharma December 9, 2024 3:03 am Indian benchmark indices settled slightly lower on Friday after the RBI's monetary policy, snapping the five-day winning streak. BSE Sensex fell 56.74 points or 0.07 per cent to end at 81,709.12. NSE's Nifty50 eased 30.60 points or 0.12 per cent, …
- Fierce Pharma Asia—Sanofi's $1B manufacturing base; GSK's ADC deal, Shingrix recalibration in China December 6, 2024 6:53 pm Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in Singapore. GSK inked an antibody-drug conjugate deal with DualityBio and, through a revised agreement with Zhifei, dialed down its …
- Active Pharmaceutical Ingredients Market To Grow By USD 86.47 Billion (2024-2028), Driven By Evolving API Manufacturing, With AI Driving Market Transformation - Technavio December 3, 2024 12:39 am (MENAFN- PR Newswire) NEW YORK, Dec. 2, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The global active Pharmaceutical ingredients market size is estimated to grow by USD 86.47 billion from 2024-2028, according to Technavio. The …
- Clariant to showcase made in India pharma products at CPHI 2024 November 26, 2024 9:38 am Clariant is excited to present the company’s latest portfolio of products for the healthcare industry at the upcoming CPHI India tradeshow in Delhi NCR on November 26 through 28, 2024. This year’s event will showcase Clariant Health Care’s Made in India …
- Stocks in news: Waaree Energies, GMR Infra, AstraZeneca, Indus Towers, Ashoka Buildcon & ITI November 19, 2024 3:09 am Indian benchmark indices settled lower on Monday, marking losses for the seventh straight session. A muted earnings season, and mixed global cues dented the sentiments at Dalal Street. BSE Sensex shed 241.30 points or 0.31 per cent to end at 77,339.01. NSE …
- Global Plant-Based API Market Set to Reach USD 52,085.9 Million by 2034, Expected to Grow at a CAGR of 5.6% | Future Market Insights, Inc. November 14, 2024 4:30 pm NEWARK, Del, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The global plant-based API market is expected to experience robust growth, with a projected value of USD 30,084.8 million in 2024, expanding at a compound annual growth rate (CAGR) of 5.6% through 2034, …
- Tryptamine API Market is Set to Reach $2.25 Billion with 11.5% CAGR by 2034 | Fact.MR Report November 6, 2024 12:30 pm Rockville, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- According to a new industry report by Fact.MR, the global tryptamine API market is projected to be worth US$ 757.2 million in 2024 and thereafter advance at 11.5% CAGR from 2024 to 2034. Tryptamine possesses …
- Piramal Pharma Limited Announces Results for Q2 and H1 FY25 October 23, 2024 6:55 pm MUMBAI, Oct. 23, 2024 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year ( …
- LGM Pharma Expands Its Analytical Testing Services October 15, 2024 1:44 pm Breaking News Adds endotoxin and rapid sterility testing capabilities to benefit drug developers. 10.15.24 LGM Pharma, a provider of tailored API and CDMO services for the full drug product lifecycle, has expanded its Analytical Testing Services (ATS) with …
- India News | JP Nadda Inaugurates International Conference of Drug Regulatory Authorities, Highlights India's Contributions to Global Health Security October 14, 2024 1:16 pm New Delhi [India], October 14 (ANI): Union Health Minister JP Nadda on Monday inaugurated the 19th International Conference of Drug Regulatory Authorities and said that the ICDRA platform provides a space to share knowledge, foster partnerships and develop …
- CPHI Milan Announces Winners of 2024 CPHI Pharma Awards October 9, 2024 4:20 pm CPHI Milan has announced the winners of the prestigious 2024 CPHI Pharma Awards, celebrating the brightest minds and most innovative advancements across the global pharmaceutical industry. This year’s awards spanned 14 categories, including two new …
- Pharma Fridays – October 4, 2024 October 4, 2024 5:45 pm An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Priority Review Granted for HER2-low or HER2-ultralow Metastatic Breast Cancer Treatment On October 1, AstraZeneca and Daiichi Sankyo announced that its …
- Sterling Pharma, Soligenix Partner to Manufacture Oncology API October 4, 2024 2:14 pm Breaking News Sterling to manufacture a GMP-quality synthetic hypericin developed by Soligenix for its oncology drug, HyBryte. 10.04.24 Sterling Pharma Solutions, a global contract development and manufacturing organization, and Soligenix, a late-stage …
- Stocks in news: Ola Electric, BSE, Bajaj Finance, RPower, CESC, Bank of Baroda, DMart & Godawari Power October 4, 2024 3:01 am Indian benchmark indices saw an intense sell-off on Thursday on the back of rising geopolitical concerns, intense FIIs selling and a reaction to SEBI's F&O curbs. BSE Sensex crashed 1,769.19 points or 2.10 per cent, to end at 82,497.10. NSE's …
- C2 PHARMA Expands Ophthalmic Portfolio October 1, 2024 8:37 pm Breaking News Plans several more product launches for the upcoming year. 10.01.24 C2 PHARMA, a leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), recently launched Naphazoline Hydrochloride, expanding its …
- Sensex drops 1272 pts, Nifty ends below 25,850 amid mixed global cues September 30, 2024 2:57 pm Domestic equity benchmarks experienced a sharp decline today, mirroring global trends, as tensions in the Middle East escalated. The Nifty50 closed below 25,850, with sectors like auto, banking, and finance bearing the brunt of the sell-off. However, …
- Stocks in news: Manba, Dr Reddy's, PNB, Zomato, IDFC First, BEL, Tata Motors & ICICI Pru September 30, 2024 3:02 am Indian benchmark indices settled lower on Friday on the back of profit booking by the traders during the fag-end session. BSE Sensex dropped 264.27 points or 0.31 per cent, to end the session at 85,571.85. NSE's Nifty50 shed 37.10 points, or 0.14 per …
- The pharma& Group Enters into an Exclusive Promotional Agreement with Tolmar, Inc. to Promote Rubraca® (rucaparib) in the U.S. for the Treatment of Metastatic Castration-Resistant Prostate Cancer September 25, 2024 9:01 am VIENNA and BUFFALO GROVE, Ill., Sept. 24, 2024 /PRNewswire/ -- pharmaand GmbH (pharma&) and Tolmar, Inc. (Tolmar) announced today an exclusive agreement for Tolmar to promote Rubraca (rucaparib) in the U.S. for the treatment of metastatic …
- Levothyroxine Sodium API Market Size to Grow USD 42 Million by 2030 at a CAGR of 4.5% | Valuates Reports September 24, 2024 3:00 pm BANGALORE, India, Sept. 24, 2024 /PRNewswire/ -- Levothyroxine Sodium API Market is Segmented by Type (EP, USP), by Application (Oral, Injection): Global Opportunity Analysis and Industry Forecast, 2024-2030. The Global Levothyroxine Sodium API …
- Stocks in news: RIL, HDFC Bank, Adani Ports, BHEL, Adani Gas, Voda Idea, ONGC, Tata Steel & HFCL September 23, 2024 2:44 am Indian benchmark indices joined the global rally on Friday, triggered by the US Fed's rate cuts and positive global cues. BSE Sensex soared 1,359.51 points or 1.63 per cent, to end at 84,544.31. NSE's Nifty50 zoomed 375.15 points, or 1.48 per cent, …
- Stocks in news: SpiceJet, Mankind Pharma, Vodafone Idea, Aarti Drugs, BHEL, RIL September 23, 2024 1:48 am Domestic markets edged higher on Friday, gaining nearly one and a half percent, largely tracking global trends. In today's trade, shares of SpiceJet, Mankind Pharma, Vodafone Idea, Aarti Drugs, BHEL, RIL among others will be in focus due to various …
- Citi Pharma commences nutraceutical exports to US September 20, 2024 11:33 pm Citi Pharma Limited (CPHL), a Pakistani pharmaceutical company, has commenced exports of nutraceuticals to the United States (US). The company announced the development in a notice to the Pakistan Stock Exchange (PSX) on Friday. “Citi Pharma, Pakistan’s …
- Pakistan’s Citi Pharma commences nutraceutical exports to US September 20, 2024 10:29 am Citi Pharma Limited (CPHL), a Pakistani pharmaceutical company, has commenced exports of nutraceuticals to the United States (US). The company announced the development in a notice to the Pakistan Stock Exchange (PSX) on Friday. “Citi Pharma, Pakistan’s …
- C2 Pharma Expands Ophthalmic API Portfolio September 12, 2024 3:36 pm Breaking News Launches Naphazoline Hydrochloride that will be produced by CMO partner SMS Lifesciences. 09.12.24 C2 PHARMA, a global provider of ophthalmic and niche active pharmaceutical ingredients (APIs), has launched its latest API, Naphazoline …
- Pharmaceutical CDMO Market Size to Achieve USD 345.6 Billion by 2033 September 11, 2024 3:00 pm Ottawa, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The global pharmaceutical CDMO market size is predicted to increase from USD 173.2 billion in 2023 to approximately USD 345.6 billion by 2033, According to Precedence Research. The pharmaceutical CDMO market is …
- Lilly and EVA Pharma Collaborate to Expand Access to Baricitinib in Low- to Middle-Income Countries September 4, 2024 7:42 pm Eli Lilly and Company and EVA Pharma announced that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. Discovered by Incyte and licensed to …
- Olon to Boost API Production with HuvePharma Italia Acquisition September 4, 2024 2:00 pm Breaking News The transaction aims to strengthen and broaden Olon’s product offering with a focus on the most strategic areas. Paolo Tubertini, CEO of Olon Group. 09.04.24 Olon, a chemical-pharmaceutical group, has announced plans to acquire HuvePharma …
- Up to 60 new jobs at Cork pharma plant as €130m modernistation plan confirmed September 2, 2024 1:26 pm One of Cork's longest established pharma manufacturing plants is to get a major modernisation and expansion programme that ensures a long and bright future for the company on Leeside. Cara Partners, a member of the Schwabe Group has announced a €130m …
- Stocks in news: Firstcry, NBCC, Gujarat Gas, NHPC, RailTel, Siemens, Emami, Biocon, SJVN & auto stocks September 2, 2024 1:45 am Indian benchmark indices ended the week on a high on Friday on optimism over rate cuts by the US Federal Reserve. BSE Sensex jumped 231.16 points or 0.28 per cent, to end the session at 82,365.77. NSE's Nifty50 gained 83.95 points, or 0.33 per cent, to …
- Fierce Pharma Asia—Sanofi's flu shot setback; DualityBio's IPO plan; UCB's China asset sale August 30, 2024 1:07 pm Sanofi has suspended distribution of its two flu vaccines in China out of concern of waning potency. BioNTech's antibody-drug conjugate partner, DualityBio, has filed for a Hong Kong IPO. UCB will offload some Chinese assets for $680 million. And more. …
- GPLS 2024: Why pharma logistics needs transparent supply chains August 23, 2024 11:54 am The seventh edition of the Global Pharma Logistics Summit (GPLS) unfolded with a robust focus on "Ownership Culture: Building Resilient Supply Chains in Pharma." Held in Mumbai and organised by Indian Transport & Logistics News (ITLN), a STAT …
- ICICI Bank, Ipca Labs, LTTS & Bajaj Consumer: SMC Global shares target prices for these 4 stocks August 19, 2024 7:32 am Amid the rising volatility in Indian stock markets, domestic brokerage SMC Global Securities has suggested four stocks- Ipca Laboratories Ltd, Bajaj Consumer Care Ltd, ICICI Bank Ltd and L&T Technology Services Ltd- to bet amid the scarce opportunities …
- Certa’s CEO Jag Lamba on enhancing pharma supply chain traceability and compliance August 14, 2024 5:39 pm With regulations like the Drug Supply Chain Security Act (DSCSA) in the United States and the European Union Medical Device Regulation (EU MDR) requiring stringent traceability, the need for robust technology solutions has never been greater. Jag Lamba, …
- Pharma Stalwarts Nudge Next-Gen Lab Innovations and Expiscate Future Challenges August 6, 2024 10:00 am By Prathiba Raju and Abhijeet Singh Hyderabad: Constructing a formidable presence in the global pharmaceutical landscape has required India to overcome numerous challenges, including cash deficits, skill gaps, regulatory hurdles, and supply chain issues. …
- Akums Drugs & Pharma stock market listing on BSE, NSE today. What GMP suggests August 6, 2024 2:06 am Shares of Akum Drugs & Pharmaceuticals are set for a muted listing at Dalal Street on Tuesday, thanks to the prevalent selloff in the broader markets and weak global sentiments. The severe carnage in the stock markets has diminished the listing …
- Major Indices Under Pressure Due to Global Selloff - Weekly Closing Report August 2, 2024 4:00 pm The trends of the major indices in the course of the week’s trading are given in the table below: The Indian stock market experienced a downturn on Friday, breaking a five-day winning streak for both the Sensex and Nifty. This correction came just a …
- Akums Drugs & Pharma IPO allotment status: Check application, latest GMP and listing date August 2, 2024 5:20 am Akums Drugs and Pharmaceuticals is scheduled to finalize the basis of allotment of its shares on Friday, August 02. Bidders will get the messages, alerts or emails for debit of their funds or revocations of their IPO mandate over the weekend or latest by …
- Sun Pharma Q1 PAT climbs 40% YoY to Rs 2,835 cr August 1, 2024 12:07 pm Sun Pharmaceutical Industries' consolidated net profit jumped 40.20% to Rs 2,835.6 crore on 5.96% rise in revenue from operations to Rs 12,652.75 crore in Q1 FY25 over Q1 FY24.Profit before tax was at Rs 3,423.5 crore in Q1 FY25, registering a growth …
- Akums Drugs & Pharma IPO subscribed 40x on Day 3 so far; QIB portion booked 50 times August 1, 2024 10:20 am The initial public offering (IPO) of Akums Drugs and Pharmaceuticals continued to attract strong investor response during the third and final day of the bidding process as institutional participants joined the party. The issue ended Day 1 with over 1.35 …
- Akums Drugs & Pharma IPO subscribed 3x on Day 2 so far; retail portion booked 7.2 times July 31, 2024 9:31 am The initial public offering (IPO) of Akums Drugs and Pharmaceuticals continued to attract strong response from investors during the second day of the bidding process. The issue, which kicked-off for bidding on Tuesday, July 31, sailed through on the first …
- Akums Drugs and Pharma IPO opens today: Should you subscribe to the issue? July 30, 2024 5:00 am The Rs 1,856.74 crore-initial public offering (IPO) of Akums Drugs and Pharmaceuticals kicks-off for bidding today, that is, Tuesday, July 30. The pharma player will be offering its shares in the fixed price band of Rs 646-679 apiece, with a lot size of 22 …
- Fierce Pharma Asia—Big Pharma's search for China deals; Enhertu's slowdown; Samsung Bio's record quarter July 26, 2024 6:55 am Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's antibody-drug conjugate star Enhertu experienced a slow quarter. Samsung Biologics' quarterly revenue crossed the 1 trillion South Korean won mark for the …
- Rusan Pharma’s API Plant in Ankleshwar Receives USFDA GMP Approval July 22, 2024 8:47 am RUSAN PHARMA PRIVATE LIMITED, a pharmaceutical company based in India specializing in the area of addiction treatment and pain management, recently announced that the United States Food and Drug Administration (USFDA) has granted Good Manufacturing …
- Share Market News: Remedium Lifecare Shares in Focus Amid Rs 200 Crore Fund Raising Buzz July 3, 2024 9:02 am Home Business Share Market News: Remedium Lifecare Shares in Focus Amid Rs 200 Crore Fund Raising Buzz In Asian markets, Seoul, Tokyo and Hong Kong were trading in the positive territory while Shanghai quoted lower. Top 5 Stocks In Focus Today Shares of …
- India's Patent Reforms: Competing on the Global Stage with China and the USA July 1, 2024 11:54 am This in-depth report examines the complex and often contentious interplay between patents and the pharmaceutical sector, highlighting the challenges and profound implications of this relationship. The symbiotic relationship between patents and the …
- Absence of Positive News Flows May Push the Market Down a Bit - Weekly Closing Report June 21, 2024 2:34 pm The Indian stock market ended the week on a slightly negative note, after a six-session rally, with the benchmark indices closing lower in a highly volatile session on Friday. The Sensex finished at 77,209.90, down 269.03 points or 0.35%, while the Nifty …